StatusThe thesis was presented on the 22 May, 2007
Approved by NCAA on the 14 June, 2007
Abstract– 0.25 Mb / in romanian
In the study are exposed results and the analysis of activity of the new immunoregulatory medicine BIOR in capsules, 5 mg each, on the immunological reactivity and natural resistence to patients with pulmonary tuberculosis.
They were examined 207 pacients of both sexes and different ages, and 50 healthy persons (laboratory control).
It was established the medicine BIOR in capsulses 5 mg each is an adaptogene of vegetable origine and rends a complicate immunocorrective action on breached parameters of immunological reactivity and natural resistance - the lowed parameters rase just to normal values and there heightened – reduce just to normal values.
The immunocorrective action the medicine BIOR realizes, influencing the metabolism of immunocompetent cells: normalizes the energetic metabolism of lymphocytes and functions of neutrophil oxidative - reactivation enzymes.
The medicine BIOR rends an immunocorrective influence in tuberculosis in a higher degree then the medicine PIMI-stimuline 3. This fact permits to recommend immunocorrective adaptogene BIOR for the rise of effectiveness of antituberculous therapy.
The medicine BIOR rends an immunocorrective influence in tuberculosis in different degree, in dependence on index of immunological reactivity or natural resistance and on damage degree of each concrete index.
The number of treatment courses, necessary for the normalization of index, depends on it: the more higher damage degree of explored index needs more courses of treatment for its normalization.
The medicine BIOR rends a immunocorrective influence in drug sensitive tuberculosis and
drug resistant pulmonary tuberculosis. This fact permits to recommend the immunocorrective
adaptogene BIOR for the rise of effectiveness of antituberculous therapy in both drug sensitive and
drug resistant pulmonary tuberculosis.